Daniela M. Lenggenhager

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Chantal Pauli · 4 shared papers, 2022–2025 · strength 0.66
   • Paper A stratified two-stage tumor molecular profiling algorithm to identify clinically actionable molecular alterations in p… DOI 10.1016/j.esmogo.2025.100134↗
   • Paper Ex vivo modeling of acquired drug resistance in BRAF - mutated pancreatic cancer organoids uncovers individual therapeu… DOI 10.1016/j.canlet.2024.216650↗
   • Paper Drug screening and genome editing in human pancreatic cancer organoids identifies drug-gene interactions and candidates… DOI 10.1016/j.xgen.2022.100095↗
2. Caroline Sophie Verbeke · 4 shared papers, 2018–2024 · strength 0.64
   • Paper Identification of tumour regression in neoadjuvantly treated pancreatic cancer is based on divergent and nonspecific cr… DOI 10.1111/his.15190↗
   • Paper Morphological Heterogeneity in Pancreatic Cancer Reflects Structural and Functional Divergence. DOI 10.3390/cancers13040895↗
   • Paper Pathology assessment of pancreatic cancer following neoadjuvant treatment: Time to move on. DOI 10.1016/j.pan.2018.04.010↗
3. Saskia Hussung · 3 shared papers, 2021–2025 · strength 0.55
   • Paper A stratified two-stage tumor molecular profiling algorithm to identify clinically actionable molecular alterations in p… DOI 10.1016/j.esmogo.2025.100134↗
   • Paper Ex vivo modeling of acquired drug resistance in BRAF - mutated pancreatic cancer organoids uncovers individual therapeu… DOI 10.1016/j.canlet.2024.216650↗
   • Paper β6-Integrin Serves as a Potential Serum Marker for Diagnosis and Prognosis of Pancreatic Adenocarcinoma. DOI 10.14309/ctg.0000000000000395↗
4. Ralph Fritsch · 3 shared papers, 2021–2025 · strength 0.55
   • Paper A stratified two-stage tumor molecular profiling algorithm to identify clinically actionable molecular alterations in p… DOI 10.1016/j.esmogo.2025.100134↗
   • Paper Ex vivo modeling of acquired drug resistance in BRAF - mutated pancreatic cancer organoids uncovers individual therapeu… DOI 10.1016/j.canlet.2024.216650↗
   • Paper β6-Integrin Serves as a Potential Serum Marker for Diagnosis and Prognosis of Pancreatic Adenocarcinoma. DOI 10.14309/ctg.0000000000000395↗
5. Petra Sántha · 3 shared papers, 2019–2024 · strength 0.53
   • Paper Identification of tumour regression in neoadjuvantly treated pancreatic cancer is based on divergent and nonspecific cr… DOI 10.1111/his.15190↗
   • Paper Morphological Heterogeneity in Pancreatic Cancer Reflects Structural and Functional Divergence. DOI 10.3390/cancers13040895↗
   • Paper Commonly Used Pancreatic Stellate Cell Cultures Differ Phenotypically and in Their Interactions with Pancreatic Cancer … DOI 10.3390/cells8010023↗
6. Sabrina Steiner · 2 shared papers, 2022–2024 · strength 0.33
   • Paper Ex vivo modeling of acquired drug resistance in BRAF - mutated pancreatic cancer organoids uncovers individual therapeu… DOI 10.1016/j.canlet.2024.216650↗
   • Paper De novo expression of gastrokines in pancreatic precursor lesions impede the development of pancreatic cancer. DOI 10.1038/s41388-022-02182-4↗
7. Maia Blomhoff Holm · 1 shared paper, 2024 · strength 0.28
   • Paper Identification of tumour regression in neoadjuvantly treated pancreatic cancer is based on divergent and nonspecific cr… DOI 10.1111/his.15190↗
8. Sönke Detlefsen · 1 shared paper, 2024 · strength 0.28
   • Paper Identification of tumour regression in neoadjuvantly treated pancreatic cancer is based on divergent and nonspecific cr… DOI 10.1111/his.15190↗
9. Manoj Amrutkar · 2 shared papers, 2019–2021 · strength 0.25
   • Paper Morphological Heterogeneity in Pancreatic Cancer Reflects Structural and Functional Divergence. DOI 10.3390/cancers13040895↗
   • Paper Commonly Used Pancreatic Stellate Cell Cultures Differ Phenotypically and in Their Interactions with Pancreatic Cancer … DOI 10.3390/cells8010023↗
10. Ivar P. Gladhaug · 2 shared papers, 2019–2021 · strength 0.25
    • Paper Morphological Heterogeneity in Pancreatic Cancer Reflects Structural and Functional Divergence. DOI 10.3390/cancers13040895↗
    • Paper Commonly Used Pancreatic Stellate Cell Cultures Differ Phenotypically and in Their Interactions with Pancreatic Cancer … DOI 10.3390/cells8010023↗
11. Christian Hirt · 2 shared papers, 2022 · strength 0.22
    • Paper Drug screening and genome editing in human pancreatic cancer organoids identifies drug-gene interactions and candidates… DOI 10.1016/j.xgen.2022.100095↗
    • Paper SF3B1 facilitates HIF1-signaling and promotes malignancy in pancreatic cancer. DOI 10.1016/j.celrep.2022.111266↗
12. Patrik Simmler · 2 shared papers, 2022 · strength 0.22
    • Paper Drug screening and genome editing in human pancreatic cancer organoids identifies drug-gene interactions and candidates… DOI 10.1016/j.xgen.2022.100095↗
    • Paper SF3B1 facilitates HIF1-signaling and promotes malignancy in pancreatic cancer. DOI 10.1016/j.celrep.2022.111266↗
13. Gerald Schwank · 2 shared papers, 2022 · strength 0.22
    • Paper Drug screening and genome editing in human pancreatic cancer organoids identifies drug-gene interactions and candidates… DOI 10.1016/j.xgen.2022.100095↗
    • Paper SF3B1 facilitates HIF1-signaling and promotes malignancy in pancreatic cancer. DOI 10.1016/j.celrep.2022.111266↗
14. Karolina S. Jabbar · 1 shared paper, 2022 · strength 0.12
    • Paper De novo expression of gastrokines in pancreatic precursor lesions impede the development of pancreatic cancer. DOI 10.1038/s41388-022-02182-4↗
15. Dilmurodjon Eshmuminov · 1 shared paper, 2022 · strength 0.12
    • Paper De novo expression of gastrokines in pancreatic precursor lesions impede the development of pancreatic cancer. DOI 10.1038/s41388-022-02182-4↗
16. Stephan A. Hahn · 1 shared paper, 2022 · strength 0.12
    • Paper De novo expression of gastrokines in pancreatic precursor lesions impede the development of pancreatic cancer. DOI 10.1038/s41388-022-02182-4↗
17. Anurag Kumar Gupta · 1 shared paper, 2022 · strength 0.12
    • Paper De novo expression of gastrokines in pancreatic precursor lesions impede the development of pancreatic cancer. DOI 10.1038/s41388-022-02182-4↗
18. Bernhard Kaspar Morell · 1 shared paper, 2021 · strength 0.12
    • Paper β6-Integrin Serves as a Potential Serum Marker for Diagnosis and Prognosis of Pancreatic Adenocarcinoma. DOI 10.14309/ctg.0000000000000395↗
19. Lena Häberle · 1 shared paper, 2018 · strength 0.12
    • Paper Pathology assessment of pancreatic cancer following neoadjuvant treatment: Time to move on. DOI 10.1016/j.pan.2018.04.010↗
20. Iréne Esposito · 1 shared paper, 2018 · strength 0.12
    • Paper Pathology assessment of pancreatic cancer following neoadjuvant treatment: Time to move on. DOI 10.1016/j.pan.2018.04.010↗
21. Hagen Klett · 1 shared paper, 2022 · strength 0.11
    • Paper Drug screening and genome editing in human pancreatic cancer organoids identifies drug-gene interactions and candidates… DOI 10.1016/j.xgen.2022.100095↗
22. Gunnar Rätsch · 1 shared paper, 2022 · strength 0.11
    • Paper SF3B1 facilitates HIF1-signaling and promotes malignancy in pancreatic cancer. DOI 10.1016/j.celrep.2022.111266↗
23. Ilaria Guccini · 1 shared paper, 2022 · strength 0.11
    • Paper SF3B1 facilitates HIF1-signaling and promotes malignancy in pancreatic cancer. DOI 10.1016/j.celrep.2022.111266↗
24. Markus Stoffel · 1 shared paper, 2022 · strength 0.11
    • Paper SF3B1 facilitates HIF1-signaling and promotes malignancy in pancreatic cancer. DOI 10.1016/j.celrep.2022.111266↗
25. Matthias J. Löhr · 1 shared paper, 2019 · strength 0.11
    • Paper Commonly Used Pancreatic Stellate Cell Cultures Differ Phenotypically and in Their Interactions with Pancreatic Cancer … DOI 10.3390/cells8010023↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.